Evidence map›Paper›PMID 29138462›Full record

ArticleScientific reports2017

The Antibacterial and Anti-inflammatory Activity of Chicken Cathelicidin-2 combined with Exogenous Surfactant for the Treatment of Cystic Fibrosis-Associated Pathogens.

Brandon J H Banaschewski, Brandon Baer, Christina Arsenault, Teah Jazey, Edwin J A Veldhuizen, Johan Delport, Tracey Gooyers, James F Lewis, Henk P Haagsman, Ruud A W Veldhuizen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Frontiers in bioengineering and biotechnology · 2020
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Brandon J H BanaschewskiDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Brandon BaerDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Christina ArsenaultDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Teah JazeyDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Edwin J A VeldhuizenDepartment of Infectious Diseases and Immunology, Division of Molecular Host Defense, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Johan DelportLondon Health Sciences Centre, London, Ontario, Canada.ORCID 0000-0002-8882-1756
Tracey GooyersLondon Health Sciences Centre, London, Ontario, Canada.
James F LewisDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Henk P HaagsmanDepartment of Infectious Diseases and Immunology, Division of Molecular Host Defense, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-4931-5201
Ruud A W VeldhuizenDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Cory YamashitaDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada. cyamash@uwo.ca.
Western University · CALondon Health Sciences Centre · CAUtrecht University · NL

Funding

CIHR
6 · The paper itself

Abstract

Cystic fibrosis (CF) is characterized by recurrent airway infections with antibiotic-resistant bacteria and chronic inflammation. Chicken cathelicin-2 (CATH-2) has been shown to exhibit antimicrobial activity against antibiotic-resistant bacteria and to reduce inflammation. In addition, exogenous pulmonary surfactant has been suggested to enhance pulmonary drug delivery. It was hypothesized that CATH-2 when combined with an exogenous surfactant delivery vehicle, bovine lipid extract surfactant (BLES), would exhibit antimicrobial activity against CF-derived bacteria and downregulate inflammation. Twelve strains of CF-pathogens were exposed to BLES+CATH-2 in vitro and killing curves were obtained to determine bactericidal activity. Secondly, heat-killed bacteria were administered in vivo to elicit a pro-inflammatory response with either a co-administration or delayed administration of BLES+CATH-2 to assess the antimicrobial-independent, anti-inflammatory properties of BLES+CATH-2. CATH-2 alone exhibited potent antimicrobial activity against all clinical strains of antibiotic-resistant bacteria, while BLES+CATH-2 demonstrated a reduction, but significant antimicrobial activity against bacterial isolates. Furthermore, BLES+CATH-2 reduced inflammation in vivo when either co-administered with killed bacteria or after delayed administration. The use of a host-defense peptide combined with an exogenous surfactant compound, BLES+CATH-2, is shown to exhibit antimicrobial activity against antibiotic-resistant CF bacterial isolates and reduce inflammation.

Indexed as

Achromobacter denitrificansAdultAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBiological ProductsChronic DiseaseCystic FibrosisDrug Resistance, BacterialFemaleHumansMaleMiddle AgedPseudomonas aeruginosaPulmonary SurfactantsRespiratory Tract DiseasesStaphylococcus aureusAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBiological ProductscalfactantCMAP27 protein, chickenPulmonary SurfactantsSurface-Active Agents

Identifiers

PMID29138462
PMCPMC5686076
OpenAlexW2767731065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.